Dissolution Performance of High Drug Loading Celecoxib Amorphous Solid Dispersions Formulated with Polymer Combinations

Pharmaceutical Research

Volumn 33, Issue 3, 2016, Pages 739-750

  Xie, Tian ^a   Taylor, Lynne S ^a  

^a PURDUE UNIVERSITY   (United States)

Author keywords

amorphous solid dispersion; crystallization; dissolution; supersaturation

Indexed keywords

BUFFER; CELECOXIB; HYDROXYPROPYLMETHYLCELLULOSE; HYDROXYPROPYLMETHYLCELLULOSE ACETATE SUCCINATE; POVIDONE; METHYLCELLULOSE; POLYMER; SOLUTION AND SOLUBILITY;

AMORPHOUS SOLID DISPERSION; ARTICLE; CRYSTAL; CRYSTALLIZATION; DISPERSION; DRUG FORMULATION; DRUG RELEASE; DRUG SOLUBILITY; LIGHT SCATTERING; MICROSCOPY; MOLECULAR WEIGHT; PRIORITY JOURNAL; RAMAN SPECTROMETRY; ANALOGS AND DERIVATIVES; CHEMISTRY; DRUG STABILITY; KINETICS; MEDICINAL CHEMISTRY; PROCEDURES; SOLUBILITY; SOLUTION AND SOLUBILITY;

CELECOXIB; CHEMISTRY, PHARMACEUTICAL; CRYSTALLIZATION; DRUG STABILITY; KINETICS; METHYLCELLULOSE; POLYMERS; POVIDONE; SOLUBILITY; SOLUTIONS; SPECTRUM ANALYSIS, RAMAN;

EID: 84957583589     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-015-1823-y     Document Type: Article

References (26)

1. Fahr A, Liu X. Drug delivery strategies for poorly water-soluble drugs. Expert Opin Drug Deliv. 2007;4(4):403-16.
2. Hancock BC, Parks M. What is the true solubility advantage for amorphous pharmaceuticals? Pharm Res. 2000;17(4):397-404.
3. Baird JA, Van Eerdenbrugh B, Taylor LS. A classification system to assess the crystallization tendency of organic molecules from undercooled melts. J Pharm Sci. 2010;99(9):3787-806.
4. Trasi NS, Taylor LS. Effect of additives on crystal growth and nucleation of amorphous flutamide. Cryst Growth Des. 2012;12(6):3221-30.
5. Van den Mooter G, Wuyts M, Blaton N, Busson R, Grobet P, Augustijns P, et al. Physical stabilisation of amorphous ketoconazole in solid dispersions with polyvinylpyrrolidone K25. Eur J Pharm Sci. 2001;12(3):261-9.
6. Kestur US, Taylor LS. Role of polymer chemistry in influencing crystal growth rates from amorphous felodipine. Crystengcomm. 2010;12(8):2390-7.
7. Kestur US, Van Eerdenbrugh B, Taylor LS. Influence of polymer chemistry on crystal growth inhibition of two chemically diverse organic molecules. Crystengcomm. 2011;13(22):6712-8.
8. Alonzo DE, Zhang GGZ, Zhou DL, Gao Y, Taylor LS. Understanding the behavior of amorphous pharmaceutical systems during dissolution. Pharm Res. 2010;27(4):608-18.
9. Sohnel O, Mullin JW. Interpretation of crystallization induction periods. J Colloid Interf Sci. 1988;123(1):43-50.
10. Ilevbare GA, Liu HY, Edgar KJ, Taylor LS. Maintaining supersaturation in aqueous drug solutions: impact of different polymers on induction times. Cryst Growth Des. 2013;13(2):740-51.
11. Abu-Diak OA, Jones DS, Andrews GP. An investigation into the dissolution properties of celecoxib melt extrudates: understanding the role of polymer type and concentration in stabilizing supersaturated drug concentrations. Mol Pharmaceut. 2011;8(4):1362-71.
12. Chen J, Ormes JD, Higgins JD, Taylor LS. Impact of surfactants on the crystallization of aqueous suspensions of celecoxib amorphous solid dispersion spray dried particles. Mol Pharmaceut. 2015;12(2):533-41.
13. Trasi NS, Taylor LS. Effect of polymers on nucleation and crystal growth of amorphous acetaminophen. Crystengcomm. 2012;14(16):5188-97.
14. Trasi NS, Oucherif KA, Litster JD, Taylor LS. Evaluating the influence of polymers on nucleation and growth in supersaturated solutions of acetaminophen. Crystengcomm. 2015;17(6):1242-8.
15. Konno H, Handa T, Alonzo DE, Taylor LS. Effect of polymer type on the dissolution profile of amorphous solid dispersions containing felodipine. Eur J Pharm Biopharm. 2008;70(2):493-9.
16. Konno H, Taylor LS. Influence of different polymers on the crystallization tendency of molecularly dispersed amorphous felodipine. J Pharm Sci-Us. 2006;95(12):2692-705.
17. Rumondor ACF, Stanford LA, Taylor LS. Effects of polymer type and storage relative humidity on the kinetics of felodipine crystallization from amorphous solid dispersions. Pharm Res. 2009;26(12):2599-606.
18. Marks JA, Wegiel LA, Taylor LS, Edgar KJ. Pairwise polymer blends for oral drug delivery. J Pharm Sci. 2014;103(9):2871-83.
19. Goddeeris C, Willems T, Van den Mooter G. Formulation of fast disintegrating tablets of ternary solid dispersions consisting of TPGS 1000 and HPMC 2910 or PVPVA 64 to improve the dissolution of the anti-HIV drug UC 781. Eur J Pharm Sci. 2008;34(4-5):293-302.
20. Janssens S, De Armas HN, Roberts CJ, Van Den Mooter G. Characterization of ternary solid dispersions of itraconazole, PEG 6000, and HPMC 2910 E5. J Pharm Sci. 2008;97(6):2110-20.
21. Al-Obaidi H, Ke P, Brocchini S, Buckton G. Characterization and stability of ternary solid dispersions with PVP and PHPMA. Int J Pharm. 2011;419(1-2):20-7.
22. Raina SA, Alonzo DE, Zhang GGZ, Gao Y, Taylor LS. Impact of polymers on the crystallization and phase transition kinetics of amorphous nifedipine during dissolution in aqueous media. Mol Pharmaceut. 2014;11(10):3565-76.
23. Mullin JW. Crystallization: Butterworth-Heinemann; 2001.
24. Myerson A. Handbook of industrial crystallization: Butterworth-Heinemann; 2002.
25. Anwar J, Boateng PK, Tamaki R, Odedra S. Mode of action and design rules for additives that modulate crystal nucleation. Angew Chem Int Ed. 2009;48(9):1596-600.
26. Warren DB, Benameur H, Porter CJH, Pouton CW. Using polymeric precipitation inhibitors to improve the absorption of poorly water-soluble drugs: a mechanistic basis for utility. J Drug Target. 2010;18(10):704-31.